|
Market Closed -
NYSE
07:00:02 07/10/26 am AEDT
|
5-day change | 1st Jan Change | ||
| 24.28 USD | -1.86% |
|
-2.92% | +1.89% |
| 23/09 | Arcus Biosciences, Inc. Announces New Data for Casdatifan as Treatment for Kidney Cancer Across Multiple Lines of Therapy | CI |
| 16/09 | TD Cowen Initiates Arcus Biosciences at Buy | MT |
| Market Cap | 3.15B 2.8B 2.62B 2.37B 4.48B 304B 4.51B 31.43B 12.22B 155B 11.82B 11.57B 498B | P/E 2026 * |
-6.98x | P/E 2027 * | -6.97x |
|---|---|---|---|---|---|
| Enterprise Value | 2.71B 2.41B 2.25B 2.04B 3.85B 261B 3.88B 27.03B 10.51B 133B 10.17B 9.95B 428B | EV / Sales 2026 * |
34.5x | EV / Sales 2027 * | 60.1x |
| Free-Float |
71.2% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
NYSE
| RCUS | Delayed | |
CBOE
| RCUS | Real-time |
Last Transcript: Arcus Biosciences, Inc.
| 1 day | -1.86% | ||
| 1 week | -2.92% | ||
| Current month | -6.00% | ||
| 1 month | -18.14% | ||
| 3 months | -19.95% | ||
| 6 months | +5.75% | ||
| Current year | +1.89% |
| 1 week | 23.96 |  | 26.35 |
| 1 month | 23.31 | | 29.5 |
| Current year | 18.52 | | 31.74 |
| 1 year | 13.71 | | 31.74 |
| 3 years | 6.5 | | 31.74 |
| 5 years | 6.5 | | 49.1 |
| 10 years | 6.3 | | 49.1 |
| Manager | Title | Age | Since |
|---|---|---|---|
Juan Jaen
PSD | President | 68 | 01/05/2015 |
Terry Rosen
CEO | Chief Executive Officer | 67 | 01/05/2015 |
Robert Goeltz
DFI | Director of Finance/CFO | 53 | 01/08/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Terry Rosen
CHM | Chairman | 67 | 01/12/2017 |
Kathryn Falberg
BRD | Director/Board Member | 65 | 18/09/2017 |
Yasunori Kaneko
BRD | Director/Board Member | 72 | 01/05/2015 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 21/8/26 | Exercice | Controller/Auditor | 8,481 | 0.0067% | ||
| 10/7/26 | Sell | Founder | -20,067 | 0.0160% | ||
| 11/6/26 | Free | Director | 22,600 | 0.0180% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.86% | -2.92% | +81.87% | +48.23% | 3.15B | |
| +4.16% | +3.42% | +49.37% | +94.17% | 74.31B | |
| +2.76% | -1.16% | +23.05% | +83.03% | 56.95B | |
| +0.24% | -1.37% | +4.08% | +37.22% | 48.3B | |
| -3.76% | -0.93% | +327.90% | +691.25% | 44.51B | |
| -2.30% | -4.06% | +25.82% | +31.42% | 43.8B | |
| +0.31% | -1.15% | +5.50% | +112.56% | 41.12B | |
| -0.11% | +2.30% | +9.19% | +58.68% | 31.07B | |
| +4.51% | +8.43% | +37.27% | +34.97% | 28.97B | |
| -1.96% | -3.38% | -9.25% | -12.85% | 24.53B | |
| Average | +0.18% | -0.29% | +55.48% | +117.87% | 39.67B | |
| Weighted average by Cap. | +0.73% | -0.50% | +56.79% | +133.53% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 78.61M 69.78M 65.3M 59.19M 112M 7.58B 113M 784M 305M 3.87B 295M 289M 12.43B | 50.68M 44.99M 42.1M 38.16M 72.06M 4.89B 72.59M 506M 197M 2.49B 190M 186M 8.01B |
| Net income | -446M -396M -371M -336M -635M -43.03B -639M -4.45B -1.73B -21.95B -1.68B -1.64B -70.57B | -443M -393M -368M -333M -629M -42.66B -634M -4.42B -1.72B -21.76B -1.66B -1.63B -69.96B |
| Net Debt | -441M -391M -366M -332M -627M -42.48B -631M -4.4B -1.71B -21.67B -1.65B -1.62B -69.66B | -102M -90.69M -84.87M -76.92M -145M -9.85B -146M -1.02B -396M -5.02B -383M -375M -16.15B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 07/10/26 | USD 24.28 | -1.86% | 820,546 |
| 05/10/26 | USD 24.74 | +1.23% | 1,390,862 |
| 02/10/26 | USD 24.44 | -3.13% | 1,041,906 |
| 01/10/26 | USD 25.23 | -2.32% | 1,362,744 |
| 30/09/26 | USD 25.83 | +0.70% | 1,361,916 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- RCUS Stock
Select your edition
All financial news and data tailored to specific country editions
